Clinical Trial 43599

Gurnee, IL 60031


FLOW is a clinical study, which will include over 3,000 people with type 2 diabetes
from 28 countries worldwide and will run for approximately 5 years.
The FLOW study is being carried out to see if semaglutide can reduce the worsening
or progression of kidney disease in people with type 2 diabetes. A previous study has
shown that using semaglutide reduced the progression of kidney disease and the risk
of cardiovascular events in some people with type 2 diabetes. Semaglutide is already
approved in some countries to treat type 2 diabetes.

Qualified Participants Must:

• Be 18 years of age or older
• Have been diagnosed with Type 2 Diabetes
• Impaired kidney function (GFR 50-75)

Qualified Participants May Receive:

• ability to ake a more active role in your own healthcare
•  regular expert medical care at healthcare facilities
• additional talks with study staff to discuss healthy lifestyle choices
•  the trial medication, care, and labs  for free

Compensation for time and travel for each competed  visit


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.